#USA #Thousand Oaks #Neurodegenerative #Capsida #AbbVie

Capsida and AbbVie: A New Era in Genetic Medicine

Capsida Biotherapeutics has recently made headlines with the announcement that AbbVie has opted into their first neurodegenerative disease program. This collaboration is not only a significant step for Capsida but also a beacon of hope for patients suffering from such conditions.

Financial Implications of the Collaboration

The agreement entails an impressive $40 million license payment to Capsida, alongside eligibility for additional milestones and royalties as the program progresses. This financial backing signifies belief from AbbVie in the potential of Capsida's innovative approaches to genetic therapies.

The Science Behind the Collaboration

At the core of this partnership is Capsida's groundbreaking engineered adeno-associated virus (AAV) capsids. These capsids have shown promise in delivering AbbVie’s novel therapeutic cargo into primate models effectively. By managing to achieve broad neuronal expression, while simultaneously de-targeting unwanted areas like the liver and dorsal root ganglia, Capsida's technology paves the way for targeted and more effective treatments.

Clinical Advancements on the Horizon

Moving forward, AbbVie has committed to advancing this program into IND-enabling studies and subsequent clinical trials. Capsida, in contrast, will focus on the manufacturing processes, thereby harnessing their expertise in creating these complex biological products. Peter Anastasiou, the CEO of Capsida, expressed enthusiasm about this phase, remarking that this decision underscores the collaborative efforts resulting in a therapy that aims to benefit patients.

Tackling Challenging Neurological Disorders

The challenges posed by traditional AAV capsids include limited targeting specificity, inefficiency in crossing the blood-brain barrier, and unwanted side effects. By leveraging neurotropic capsids, the collaboration aims to create solutions that can specifically deliver genetic medicine therapeutics to the central nervous system, addressing critical gaps in current treatment methodologies. Jonathon Sedgwick from AbbVie highlighted this innovative approach as vital for the successful application of gene therapies in neurology.

Background of the Partnership

This milestone arises from a strategic collaboration and licensing agreement initiated back in 2021. The goal has been to innovate and develop targeted genetic therapies addressing three neurodegenerative diseases. With a robust AAV engineering platform, Capsida is strategically positioned to deliver therapies that comprehensively treat neurological disorders, enhancing the quality of life for affected individuals.

Looking Ahead

Capsida is not just resting on its laurels; the firm has two additional wholly-owned CNS programs set to enter clinical trials in the first half of 2025. With the momentum of this partnership, there's a palpable anticipation within both organizations regarding the advancements in neurodegenerative therapies.

About Capsida Biotherapeutics

Founded in 2019, Capsida Biotherapeutics has established itself as a key player in gene therapy, focusing on the central nervous system pipeline. The firm's ambitious projects include first-in-class treatments targeting challenges like STXBP1 developmental and epileptic encephalopathy and therapies aimed at conditions such as Friedreich’s ataxia and Parkinson's disease.

Furthermore, Capsida is forming partnerships with industry giants such as Lilly and CRISPR Therapeutics, allowing for a collaborative approach to tackling some of the most pressing neurological issues in modern medicine.

This thriving company promises to drive significant advancements in genetic medicine, aiming for a future where effective treatments for neurodegenerative diseases are not only a possibility but a tangible reality.

To learn more about Capsida and its initiatives, visit their website at www.capsida.com.